Resultados del ejercicio finalizado el 31 de diciembre de 2023
The information contained within this announcement was deemed by Deltex Medical Group PLC to constitute inside information as stipulated under the UK Market Abuse Regulation
28 de marzo de 2024
Grupo médico Deltex plc
("Deltex Medical" o el "Grupo")
Resultados del ejercicio finalizado el 31 de diciembre de 2023
Deltex Medical Group plc (AIM: DEMG) today announces its results for the year ended 31 December 2023.
DESTACADOS
Finanzas
? Successfully completed the restructuring of the business and achieved annualised cost savings of approximately £1.0 million
? Revenues of £1.8 million (2022: £2.5 million), primarily reflecting the impact from unexpected delays in releasing the new TrueVue monitor and difficult market conditions
? EBITDA ajustado de £(0.9) millones (2022: £(0.6) millones)
? £1.89 million fundraise completed in August 2023 with net proceeds successfully used to strengthen the balance sheet and implement the Group's restructuring plan
? Achieved a 31% reduction in overheads (excluding exceptional costs) to £2.0 million (2022: £2.9 million). The annualised reduction in overheads is expected to be c. £1 million
? Gross cash expenditure on research and product development by the Group (excluding the effect of grants or capitalisation of product development) amounted to £0.6 million (2022: £0.8 million). The net amount, having taken into account grants, was £0.4 million (2022: £0.7 million).
? Cash in hand at 31 December 2023 of £0.7 million (2022: £0.5 million)
Actividades empresariales/comerciales
? Lanzamiento de la nueva TrueVue monitor in the UK and the EU with encouraging interest levels from existing legacy monitor users and orders now increasing, suggesting a large potential replacement market
? Markets in the Middle East, Asia and South America also being targeted for the new TrueVue monitor where Europe's CE mark is recognised, with preparatory work also underway for local regulatory approvals
? Work started on the FDA 510(k) premarket regulatory filing for the new TrueVue monitor which, when approved, will enable sales into the USA which are expected to start in 2025
? Good progress in securing production efficiencies associated with the manufacture of the new TrueVue monitorear
? Ongoing successful development work on a new non-invasive Doppler-based haemodynamic monitoring device incorporating Deltex Medical's core oesophageal doppler monitoring ("ODM") technology with a substantial addressable market
? Implementation of new lower cost and more efficient digital marketing strategies in line with the Group's new "zero-based budgeting" approach
? Have met the operational and internal financial targets agreed by the Board for the first quarter and the outlook is positive
Commenting on the results, Nigel Keen, Chairman of Deltex Medical, dijo:
"2023 was a difficult year for the Group; however, we have successfully refinanced the business and reduced our cost base substantially and I am pleased to be able to report that 2024 has started well."
"We also launched the new TrueVue monitor and see a significant upgrade and replacement market."
"Good progress is being made on a new, easy-to-use non-invasive device which sits on the same platform as Deltex Medical's core ODM technology."
Para más información, por favor póngase en contacto con:
Grupo médico Deltex plc | 01243 774 837 |
Nigel Keen, presidente | |
Andy Mears, director ejecutivo | |
Natalie Wettler, directora financiera del grupo | |
| |
Allenby Capital Limited - Asesor designado y Broker | 020 3328 5656 |
Jeremy Porter / Vivek Bhardwaj (Finanzas corporativas) | |
Tony Quirke / Stefano Aquilino (Ventas y corretaje corporativo) |
Notas para los editores
La tecnología de Deltex Medical
El sistema TrueVue de Deltex Medical utiliza tecnología de monitorización hemodinámica patentada para ayudar a los médicos a mejorar los resultados para los pacientes, así como aumentar el rendimiento y la capacidad de los hospitales.
Deltex Medical ha invertido a largo plazo para construir un cuerpo único de evidencia publicada y revisada por pares de una cantidad sustancial de ensayos realizados en todo el mundo. Estos estudios demuestran mejoras estadísticamente significativas en los resultados clínicos que brindan beneficios tanto a los pacientes como a los sistemas hospitalarios al aumentar el rendimiento de los pacientes y expandir la capacidad del hospital.
La monitorización Doppler esofágica ("ODM") basada en ultrasonido, líder mundial y emblemática del Grupo, está respaldada por 24 ensayos de control aleatorios realizados en pacientes anestesiados. Como resultado, la aplicación principal de ODM se centra en guiar la terapia para pacientes sometidos a cirugía electiva, aunque los pacientes sedados en cuidados intensivos siguen siendo una parte importante de nuestro negocio. El nuevo monitor de próxima generación del Grupo hace que el uso de la tecnología ODM sea más intuitivo y proporciona datos aumentados sobre el estado de cada paciente.
Los ingenieros y científicos de Deltex Medical llevaron a cabo una investigación exitosa en conjunto con el Laboratorio Nacional de Física ("NPL") del Reino Unido, lo que ha permitido que la tecnología ODM "estándar de oro" del Grupo se amplíe y desarrolle para que pueda usarse de manera completamente no invasiva. Esto ampliará significativamente la aplicación de la tecnología de Deltex Medical a pacientes no sedados. Esta nueva mejora tecnológica, que se lanzará en el nuevo monitor de próxima generación, aumentará sustancialmente el mercado al que se dirigen las tecnologías de monitorización hemodinámica del Grupo y es complementaria a la base de pruebas ODM establecida desde hace mucho tiempo.
La nueva tecnología no invasiva de Deltex Medical tiene aplicaciones potenciales para su uso en varios entornos de atención médica, que incluyen:
§ Accidentes y Emergencias para la clasificación rápida de pacientes, incluida la detección y el diagnóstico de sepsis;
§ en salas generales para ayudar a facilitar un régimen de tratamiento en tiempo real basado en datos para pacientes cuya condición podría deteriorarse rápidamente; y
§ en unidades de cuidados intensivos para permitir el seguimiento regular de los pacientes después de la cirugía que ya no están sedados ni intubados.
Una de las oportunidades clave para el Grupo es posicionar esta nueva tecnología no invasiva para su uso en todo el hospital. Las tecnologías de monitorización hemodinámica de Deltex Medical proporcionan a los médicos información en tiempo real, latido a latido, sobre el volumen de sangre circulante y la función cardíaca del paciente. Esta información es fundamental para que los médicos puedan optimizar la administración de líquidos y fármacos a los pacientes.
El modelo comercial de Deltex Medical consiste en impulsar los ingresos recurrentes asociados con la venta de sondas ODM desechables de un solo uso que se utilizan en el sistema TrueVue y complementar estos ingresos con un nuevo flujo de ingresos incremental que se derivará de la nueva tecnología no invasiva del Grupo. .
Tanto la sonda ODM de un solo uso existente como el nuevo dispositivo no invasivo se conectarán al mismo monitor TrueVue que se lanzó al mercado en noviembre de 2023. Los monitores se venden o, debido a los tiempos de adquisición de capital a menudo prolongados de los hospitales artículos, podrán prestarse para fomentar una adopción más rápida de la tecnología del Grupo.
Clientes de Deltex Medical
Los principales usuarios de los productos de Deltex Medical son actualmente los anestesistas que trabajan en el quirófano de un hospital y los intensivistas que trabajan en las UCI. Este perfil de cliente cambiará a medida que el mercado adopte la nueva tecnología no invasiva del Grupo. En el Reino Unido, el Grupo vende directamente al NHS. En EE. UU., el Grupo vende directamente a una variedad de sistemas hospitalarios. El Grupo también vende a través de distribuidores en más de 40 países de la Unión Europea, Asia y América.
El objetivo de Deltex Medical
Ver la adopción del nuevo monitor TrueVue de Deltex Medical, que comprende tecnologías mínimamente invasivas y no invasivas, como estándar de atención en monitorización hemodinámica para todos los pacientes, desde recién nacidos hasta adultos, despiertos o anestesiados, en todos los entornos hospitalarios del mundo.
Para más información por favor vaya a www.deltexmedical.com
PRESIDENTE DECLARACIÓN
Introducción
We are pleased to report that we successfully completed the restructuring of the Group's business as well as achieving annualised cost savings of approximately £1.0 million. We have since met the operational and internal financial targets agreed by the Board for the first quarter of the year and the outlook is positive.
Notwithstanding 2023 initially being a difficult year for Deltex Medical, 2023 saw a number of key milestones achieved by the Group, including the successful turnaround of the business.
Deltex Medical faced three principal challenges which together contributed to the Group needing to carry out a fundraise, details of which were announced by Deltex Medical on 14 July 2023 (the "Fundraise"). These challenges comprised:
§ a continuing slow pick-up in activity levels post the end of the Covid-19 pandemic;
§ extended lead times for certain specific components needed to complete the new TrueVue monitor development, largely related to post Covid-19 supply chain issues. This resulted in the slippage of the launch date for the new TrueVue monitor; and
§ delays in orders and the award of a national tender for haemodynamic monitoring with one of the Group's Latin American distributors which had been expected to have strong short-term prospects for cash generation.
The Fundraise has enabled the Group to turnaround its business with the result that:
§ the cost base of the Group has been significantly reduced, bringing down the cashflow breakeven point substantially;
§ lower cost and more efficient digital marketing techniques have been adopted which are expected to help drive incremental revenues albeit with smaller salesforces in the UK and USA; and
§ el nuevo TrueVue monitor was completed and launched in the UK and Europe, as well as global markets that recognise the EU's 'CE mark', in November 2023.
Since its launch, a number of existing users of the Group's oesophageal Doppler monitoring technology have shown strong levels of interest in the new TrueVue monitor with orders now increasing. In parallel, good progress has been made by the Group in relation to streamlining the manufacturing processes associated with the new monitor.
Finanzas dE TRATAMIENTOS
Group revenues for the year ended 31 December 2023 decreased by 28% to £1.8 million (2022: £2.5 million) primarily reflecting difficult market conditions and the delayed launch to the new TrueVue monitor. These issues collectively adversely affected the sales of the Group's single-use disposable ODM probes which declined to £1.4 million (2022: £1.8 million).
As a proportion of total Group revenues, direct sales into the USA and UK remained broadly unchanged at 50% (2022: 51%).
Deltex Medical's European customers have been aware of the expected launch of the new TrueVue monitor and during the year became increasingly reluctant to purchase the previous generation monitor. As a result, monitor revenues reduced by 52% to £258,000 (2022: £537,000).
The reduction in activity levels also adversely affected overhead recovery in the Chichester production facility, resulting in the Group's gross margin reducing to 63% (2022: 74%).
Overheads, excluding exceptional costs, disminuido en 31% to £2.0 million (2022: £2.9 millón).
The exceptionals of £366,000 largely related to restructuring costs, namely reducing the Group's headcount, including payments in lieu of notice, redundancy costs and associated legal fees. In addition, £141,000 was associated with writing off research and development projects not taken forward.
Adjusted EBITDA (comprising earnings before interest, tax, depreciation and amortisation, share-based payments and non-executive directors' fees) was a loss of £(860,000) (2022: £(607,000)). Adjusted EBITDA is reconciled to operating loss in note 3.2 de lo financiero Declaraciones.
Gross cash expenditure on research and product development by the Group (excluding the effect of grants or capitalisation of product development) amounted to £0.6 million (2022: £0.8 million). The net amount, having taken into account grants, was £0.4 million (2022: £0.7 million). This year-on-year reduction reflects that the majority of the costs for the development work on the new TrueVue monitor were incurred before 2023.
Operating loss for the year was £(1.1) million (2022: £(0.9) million). Loss for the year was £(1.3) million (2022: £(1.1) million).
El efectivo disponible a 31 de diciembre de 2023 era de £0.7 millones (2022: £0.5 millones).
Empresa actividades
Deltex Medical sells directly, via its own sales teams, into UK and US hospitals, and via a network of distributors into approximately 40 other international territories.
The Group's direct sales teams continue to experience constraints in being able to access clinicians in UK and US hospitals' operating theatres ("ORs") and intensive care units ("ICUs"). These constraints were imposed by UK and US hospitals during the Covid-19 pandemic, and many of these constraints remain in place notwithstanding the end of the pandemic.
Despite 2023 being a challenging year for the Group, progress was made on a number of fronts including:
§ the launch of the new monitor;
§ development work on the new, novel non-invasive device;
§ a substantial reduction in costs - leading to a significantly lower breakeven point; and
§ improved marketing following adoption of new digital techniques.
These items are more fully described in the accompanying Business Review.
The Board remains focussed on the importance of cash generation. Accordingly, Deltex Medical's business development activities are increasingly focused on ensuring significant incremental increases in revenues from a small number of existing and targeted prospective customers.
Empleados
On behalf of the Board, I would like to thank all of the Group's employees for their hard work during what was a challenging and at times stressful year.
I would also like to thank Julian Cazalet, Mark Wippell and Tim Irish who retired as non-executive directors of the Group on 1 December 2023. Together they have been a source of invaluable wise counsel and sound advice over a number of years.
We were separately delighted to welcome Ben Carswell to the Board on 1 December as a non-executive director.
Comercio actual y perspectivas
El launch of the new, next generation TrueVue monitor is a key milestone for the Group, with the first sale of the new TrueVue monitor having taken place at the end of November 2023.
We are seeing encouraging levels of interest in this product from the UK and our international distributors. Work has already started on the FDA 510(k) premarket regulatory submission to the US Food and Drug Administration (the "FDA") which, once regulatory approval has been received, will enable us to sell the new monitor into the US market.
We are continuing to drive forwards the development of our new non-invasive device. We believe the new device will be used in clinical areas not served well by our existing products and will therefore allow us to sell into significantly larger markets.
We continue to focus on optimising the commercial opportunities associated with a small number of significant tenders, including in Latin America, where we believe that Deltex Medical's ODM technology has strong opportunities to take market share.
After a tough 2023, I am pleased to be able to report that 2024 has started well and we are much encouraged for the future.
Nigel Keen
Presidente
27 marzo 2024
NEGOCIOS REVIEW
General
Deltex Medical is a world leader in high accuracy oesophageal Doppler monitoring, via its TrueVue platform, which allows real-time monitoring by clinicians of a patient's haemodynamic status.
More than twenty peer-reviewed, randomised controlled trials have demonstrated that an ODM-driven haemodynamic protocol can result in statistically significant reductions in post-operative complications such as acute kidney injuries, resulting in lower costs for hospitals due to shorter patient length-of-stay. The use of the ODM technology is good for patients. It also increases throughput and capacity for hospitals, which should help reduce the backlog in elective surgery, which is a particular issue in the United Kingdom.
Deltex Medical's technology was originally developed in a London ICU to assist with the treatment of acutely unwell critical care patients. Over time demand for the Group's high fidelity ODM-based haemodynamic monitoring technology has migrated from the ICU to the OR, particularly for complex elective surgical procedures; however, there are now signs of increasing interest from ICUs in the ODM technology.
Before the Covid-19 pandemic, approximately 80% of the Group's revenues were associated with elective surgical procedures in ORs. The near-complete cessation of elective surgery during the pandemic was highly disruptive to Deltex Medical's commercial activities, particularly in the UK and the USA, where the Group sells its technology to hospitals directly.
A pesar de que, post-pandemic, elective surgery has restarted around the world, dispositivo médico sales teams, including Deltex Medical's, are still experiencing more restricted levels of access to ORs and ICUs than they enjoyed pre-pandemic.
Lanzamiento de la nueva TrueVue monitorear
After a number of years in development, the Group released its new TrueVue monitor onto the market in November 2023. The development of the new device had taken longer than expected as a result of disrupted supply chains during, and for some time after, the Covid-19 pandemic.
The new monitor has been designed to act as a platform for a range of complementary technologies, including a new, novel non-invasive device that the Group is also developing.
Orders for the new TrueVue monitor are increasing which is encouraging. There is a substantial domestic and international replacement and upgrade market, which it is anticipated will drive orders in the short to medium term. In addition, the Group expects to see probe orders increasing based on new monitor equipment sales.
El nuevo TrueVue monitor has been designed with production engineering input in order to reduce the prime costs of the equipment as well as enhance its overall reliability. Good progress has been made with reducing the labour hours required for each of the sub-assemblies as the Group streamlines its manufacturing processes. Overall, the gross margin on the new TrueVue monitor is expected to be higher than the previous unit, although price points vary significantly between direct sales into the UK (as well as, post launch, the USA) and overseas sales to distributors.
Work has started on assembling the necessary documents required for the 510(k) premarket regulatory submission to the US FDA. It is planned that the FDA filing process should be completed in 2025 and sales of the new monitor into the US market should follow shortly thereafter.
Dispositivo no invasivo
Deltex Medical's current ODM device is principally used on sedated patients: typically those admitted to ICUs or being operated on within ORs. The resultant haemodynamic data derived from the ODM technology is extremely accurate and has been shown in some 24 published randomised controlled trials to be associated with significantly improved patient outcomes and reduced costs to hospitals as a result of shorter hospital stays. However, limiting the use of this technology just to patients in ICUs and ORs self-evidently reduces the size of the addressable market and constrains the Group's revenues.
The new non-invasive Doppler-based haemodynamic monitoring device that the Group is developing is designed to use the same underlying oesophageal Doppler haemodynamic monitoring technology which is supported by a large body of published literature. However, a different, novel design will enable the technology to be used non-invasively and thus on a much larger patient population.
Although this new non-invasive device is still in the development phase, the Group is working on the basis that it should ultimately end up representing a form of digital haemodynamic stethoscope. This will give healthcare workers, from doctors to nurses across a range of departments, immediate access to high quality, real time haemodynamic data for patients. In turn, these data are anticipated to give rise to improved and more rapid treatment of patients throughout a hospital or other clinical care-giving facility such as the emergency services or a primary care doctor's office.
Deltex Medical believes that this new, non-invasive device, with a substantially larger addressable market, represents a significant opportunity for the Group to drive substantial profitable growth.
In parallel with working on the technical development aspects of this new, novel non-invasive technology, Deltex Medical is carrying out structured 'voice of the customer' discussions with prospective hospital-based users to determine how best to launch, and charge for, this new non-invasive ODM technology. Discussions with a number of the Group's international distributors suggest that there could be significant overseas market demand when this new device is launched.
Three principal divisions: UK, USA and Internacional
Las actividades comerciales de Deltex Medical se estructuran en tres divisiones: Reino Unido; USA e Internacional.
The Group has faced difficulties in driving its commercial activities back to those levels seen pre the Covid-19 pandemic in its two direct sales territories of the UK and the USA. Many hospitals have imposed significant restrictions on salespersons or clinical educators accessing ORs or ICUs. Once any hospital stops using Deltex Medical's ODM technology, it can take time and significant resources to re-instigate the use of the technology as the clinical staff change rapidly and new staff need to be trained on the use of ODM.
Deltex Medical has also been restricting expenditure on sales and marketing activities in the UK and USA in advance of the launch of the new monitor.
One way in which the Group has been seeking to mitigate the impact of its reduced sales and marketing spend, as well as the impact of greater restrictions on sales teams meeting hospital-based decision-makers in person, is by increasing the use of digital marketing materials. The Group is adopting a number of digital marketing techniques as well as training via the launch of its online Deltex Medical Academy.
The Group monitors closely per user probe revenues. Internal analyses demonstrate that only small increases in per (hospital) account probe purchases, or the successful adoption of the ODM technology by a small number of new, high-volume users, should drive the Group to positive cashflow.
There remains a substantial, and increasing, backlog in elective surgery as a result of the Covid-19 pandemic. In the UK the adverse effects of this backlog on patients have been exacerbated by a number of strikes by NHS healthcare workers. This backlog represents both an opportunity and a challenge for the Group. For example, there are powerful arguments, supported by the published evidence base, that the use of Deltex Medical's TrueVue technology increases patient throughput in a hospital and improves patient outcomes, thereby helping to reduce the size (and associated cost) of the backlog. Conversely, there is some anecdotal evidence that certain NHS hospitals, under pressure to reduce the backlog, are reluctant to promote the adoption of new and/or different technologies.
Following the launch of the new TrueVue monitor, Deltex Medical has now notified all UK hospitals that the previous legacy version (CardioQ-ODM+) is now obsolete. The Group has a regulatory requirement to provide service support to maintain these devices for ten years. Many NHS hospitals with the previous monitor are expected to apply for funding from capital replacement programmes to purchase the new monitor.
As it will take some time to complete the submissions required to receive FDA approval for the new TrueVue monitor, the Group's US operation has been tasked with supporting as many existing customers as possible in order to drive up probe sales, whilst cultivating these existing relationships in advance of the launch of the new TrueVue monitor into the US market, which is expected to be next year.
The International division, with its team of some 40 overseas distributors, continues to represent an important route to market for the Group's products. International sales represent approximately half of the Group's revenues.
In the first quarter of 2024, the new TrueVue monitor has been demonstrated at three large international medical exhibitions. Deltex Medical attended Arab Health in January 2024, which is now one of the largest medical device exhibitions worldwide, where it also met with a number of its distributors. Deltex Medical also attended the Korea International Medical & Hospital Equipment Show (KIMES) in Seoul, as historically the legacy monitor sold well in South Korea.
Earlier this month, the Group exhibited at the World Congress of Anaesthesia (WCA) in Singapore which is held every four years. The advantages of using Deltex Medical's technology were presented at the WCA by a clinician who presented data that demonstrated that the ODM technology should be used on young fit patients; and not just sick elderly patients.
Although the Latin American contract that the Group was awarded last year has not developed as rapidly as was first expected, there are encouraging signs that over the next couple of years this contract will be an important source of revenues to Deltex Medical. In this respect, it is encouraging that some hospitals in that market have already started to purchase probes that are linked to this contract.
Desarrollo de productos y innovación
During 2023, the research and development team were focussed on completing the development of the new TrueVue monitor. This included the completion of complex and onerous regulatory testing, including electromagnetic compatibility (EMC) testing.
Notwithstanding that the successful development of the new monitor was the Group's priority, research work also continued on the development of the new, novel non-invasive haemodynamic monitoring technology, including the integration of the recommendations of the National Physical Laboratory arising from Deltex Medical's collaborative research work with them.
In addition to the development work on the new non-invasive device, work continues in relation to supporting the launch of the new TrueVue monitor.
Regulador
Deltex Medical designs and manufactures Class II medical devices which it sells around the world. As a result, its business activities can be significantly affected by changes to regulations. The post-Brexit regulatory regime in the UK, as well as for UK companies selling into Europe, is still evolving and the Group keeps actual or prospective changes in applicable regulations under close scrutiny.
In Europe the transition from the Medical Device Directive to the European Medical Device Regulation ("MDR") has been deferred until 2028. Although this reduces some regulatory-associated complexity in the short term, there is still considerable uncertainty as to what steps will be required, and by when, for a Class II medical device manufacturer to comply with MDR in the future.
Investment in the Group's regulatory activities remains an important part of the business and is critical for its future success.
Conclusión
Completion of the new TrueVue monitor tiene greatly enhanced Deltex Medical's technological offering to the market as well as opening up the possibility to use this instrument as a platform for further product line extensions. We are particularly interested in the commercial potential, and significantly larger addressable market, associated with the easier-to-use non-invasive haemodynamic monitoring technology which we are desarrollando.
Initial market feedback and demand for the new monitor has been encouraging, both from existing and prospective customers. We see its launch as a critical building block in driving up probe revenues across all three of the Group's divisions.
Our key challenge is to commercialise the Group's new technologies successfully from our significantly lower cost base by maximising the use of digital marketing. As we start to generate cash, we will be able to initiate further sales initiatives to drive up revenues.
We are pleased with the progress that we have made to date in 2024.
andy mears
Director
27 de marzo de 2024
Estado consolidado de resultados integrales ingresos
Por el año terminado el 31 de diciembre 2023
| 2023 000 £ | 2022 000 £ | |
Ingresos |
| 1,776 | 2,482 |
Costo de ventas |
| (651) | (643) |
Bruto beneficio | 1,125 | 1,839 | |
Administrativo gastos | (1,081) | (1,560) | |
Ventas y distribuciones gastos | (685) | (1,027) | |
Research and Development, Quality and Regulador | (217) | (231) | |
Impairment loss on trade cuentas por cobrar Costos excepcionales |
| - | (39) - |
Total costos |
| (2,349) | (2,857) |
Otro ganancia |
| 172 | 71 |
Funcionamiento de | (1,052) | (947) | |
Finanzas costos |
| (230) | (199) |
Pérdida antes impuestos | (1,282) | (1,146) | |
Tax credit on de |
| - | 1 |
Pérdida por el año | (1,282) | (1,145) | |
Otro integral gastos | |||
Elementos que pueden ser reclasificados a resultados o pérdida: Net translation differences on overseas filiales |
5 |
35 | |
Other comprehensive expense for the year, net of deuda | 5 | 35 | |
Pérdida integral total para el año | (1,277) | (1,110) | |
Pérdida integral total del año atribuible para: | |||
Dueños del Padre | (1,252) | (1,114) | |
Sin control intereses | (25) | 4 | |
(1,277) | (1,110) | ||
Pérdida por acción - básico y diluido |
|
(0.11p) |
(0.17p) |
Consolidated balance hoja | |||
Al 31 de diciembre 2023 Numero de compañia 03902895 | |||
| 2023 | 2022 | |
000 £ | 000 £ | ||
Activos | |||
No corriente activos | |||
Propiedad, planta y equipo |
| 198 | 269 |
Intangible activos |
| 3,965 | 3,769 |
Total no corriente activos | 4,163 | 4,038 | |
Current activos | |||
Los inventarios |
| 716 | 821 |
Trading cuentas por cobrar |
| 177 | 456 |
Activos financieros a amortizar el costo |
| - | 15 |
Otra corriente activos |
| 87 | 140 |
Impuesto sobre la renta corriente recuperable | 84 | 72 | |
Efectivo y efectivo equivalentes | 705 | 471 | |
Corriente Total activos | 1,769 | 1,975 | |
Total activos | 5,932 | 6,013 | |
Pasivos | |||
Current pasivo | |||
Préstamos |
| (79) | (935) |
Comercio y otros cuentas por pagar |
| (855) | (1,540) |
Corriente Total pasivo | (934) | (2,475) | |
No corriente pasivo | |||
Préstamos |
| (1,665) | (1,069) |
Comercio y otros cuentas por pagar |
| (119) | (177) |
Provisiones |
| (71) | (64) |
Total no corriente pasivo | (1,855) | (1,310) | |
Total pasivo | (2,789) | (3,785) | |
Red activos | 3,143 | 2,228 | |
Equidad | |||
Compartir capital |
| 7,204 | 6,990 |
Compartir producto de más alta calidad. |
| 35,650 | 33,672 |
Redención de capital reserva |
| 17,476 | 17,476 |
Otro reserva |
| 473 | 527 |
Traducción reserva |
| 173 | 168 |
Nota de préstamo convertible reserva |
| 82 | 82 |
Acumulado pérdidas |
| (57,769) | (56,566) |
Patrimonio atribuible a los propietarios de los Padre | 3,289 | 2,349 | |
Sin control intereses | (146) | (121) | |
Total equidad | 3,143 | 2,228 |
*Prior year restatement relates to an offset of a debtor and creditor balance
|
Capital social |
Compartir premium | Redención de capital reserva |
Otra reserva | Convertible nota de préstamo reserva |
Traducción reserva |
Acumulado pérdidas |
Total | No- CONTROL intereses |
Total equidad | |
000 £ | 000 £ | 000 £ | 000 £ | 000 £ | 000 £ | 000 £ | 000 £ | 000 £ | 000 £ | |
Saldo a los 1 Enero | ||||||||||
2023 | 6,990 | 33,672 | 17,476 | 527 | 82 | 168 | (56,566) | 2,349 | (121) | 2,228 |
Comprensiva | ||||||||||
de | ||||||||||
Pérdida por el período | - | - | - | - | - | - | (1,257) | (1,257) | (25) | (1,282) |
Otro resultado integral del período | - | - | - | - | - | 5 | - | 5 | - | 5 |
Total exhaustivo | - | - | - | - | - | 5 | (1,257) | (1,252) | (25) | (1,277) |
pérdida por año | ||||||||||
Transacciones | ||||||||||
dueños de la Grupo procesos | ||||||||||
Acciones emitidas durante | 214 | 2,171 | - | - | - | - | - | 2,385 | - | 2,385 |
las año | ||||||||||
Inconveniente gastos | - | (193) | - | - | - | - | - | (193) | - | (193) |
Mudanzas | - | - | - | (54) | - | - | 54 | - | - | - |
Balance at 31 diciembre 2023 | 7,204 | 35,650 | 17,476 | 473 | 82 | 173 | (57,769) | 3,289 | (146) | 3,143 |
Estado de cambios en el patrimonio neto consolidado del ejercicio finalizado el 31 de diciembre 2022
Capital social |
Compartir premium | Redención de capital reserva |
Otra reserva | Convertible nota de préstamo reserva |
Traducción reserva |
Acumulado pérdidas |
Total | No- CONTROL intereses Total equidad | |
000 £ | 000 £ | 000 £ | 000 £ | 000 £ | 000 £ | 000 £ | 000 £ | 000 £ 000 £ | |
Saldo a los 1 Enero | |||||||||
2022 | 5,849 | 33,502 | 17,476 | 573 | 82 | 133 | (55,588) | 2,027 | (125) 1,902 |
Comprensiva | |||||||||
de | |||||||||
Pérdida por el período | - | - | - | - | - | - | (1,149) | (1,149) | 4 (1,145) |
Otro exhaustivo | - | - | - | - | - | 35 | - | 35 | 35 |
ingreso para el período | |||||||||
Total exhaustivo | - | - | - | - | - | 35 | (1,149) | (1,114) | 4 (1,110) |
pérdida por año | |||||||||
Transacciones | |||||||||
dueños de la Grupo procesos | |||||||||
Acciones emitidas durante | 1,141 | 285 | - | - | - | - | - | 1,426 | - 1,426 |
las año | |||||||||
Gastos de emisión | (115) |
| (115) | (115) | |||||
liquidado en acciones Participación | - | - | - | 125 | - | - | - | 125 | - 125 |
basado pago | |||||||||
Mudanzas | - | - | - | (171) | - | - | 171 | - | - - |
Balance at 31 diciembre 2022 | 6,990 | 33,672 | 17,476 | 527 | 82 | 168 | (56,566) | 2,349 | (121) 2,228 |
Estado consolidado de efectivo flujos | ||
para el año terminado el 31 de diciembre 2023 | ||
2023 000 £ |
2022 000 £ | |
Flujos de efectivo de operación actividades | ||
Pérdida antes impuestos | (1,282) | (1,146) |
Ajustes para: | ||
Finanzas costos | 230 | 199 |
Depreciación de propiedades, planta y equipo | 110 | 88 |
Amortización de intangibles activos | 23 | 40 |
Pérdida por enajenación de propiedades, planta y equipo | 11 | - |
Write off of research and development projects not taken forward | 141 | - |
Modification gain on convertible loan note | (89) | - |
Non-Executive Director fees | 91 | - |
Pagos basados en acciones gastos | - | 125 |
Otro ganancia | (83) | (71) |
Efecto del tipo de cambio fluctuaciones del mercado. | 5 | 35 |
(843) | (730) | |
Decrease/(Increase) in inventarios | 105 | (48) |
Decrease/(Increase) in trade and other cuentas por cobrar | 332 | (57) |
(Decrease)Increase in trade and other cuentas por pagar | (691) | 306 |
Decrease in staff advances | 15 | - |
Aumento En provisiones | 7 | 7 |
Efectivo neto utilizado en operaciones | (1,075) | (522) |
Interés dinero | (191) | (153) |
RDEC taxes recibido | 71 | 69 |
Efectivo neto utilizado en operaciones actividades | (1,195) | (606) |
Flujos de efectivo de la inversión actividades | ||
Compra de propiedad, planta y equipo | (9) | (70) |
Capitalised development expenditure (net of subsidios) | (361) | (674) |
Efectivo neto utilizado para invertir actividades | (370) | (744) |
Cash flows from / (used in) financing actividades | ||
Issue of ordinary share capital | 1,887 | 1,340 |
Expenses in connection with share | (193) | (115) |
Net movement in invoice discount facilidad | (106) | (17) |
Línea de préstamo standby reembolso | - | (500) |
Línea de préstamo standby drawdown | 250 | 750 |
Arrendamiento principal pagos | (52) | (45) |
Efectivo neto generado por financiamiento actividades | 1,786 | 1,413 |
Aumento / (disminución) neto de efectivo y efectivo equivalentes | 221 | 63 |
Efectivo y equivalentes de efectivo al inicio del período | 471 | 413 |
Exchange loss on cash and cash equivalentes | 13 | (5) |
Efectivo y equivalentes de efectivo al final del período | 705 | 471 |
1. Naturaleza de la información financiera
Este Resumen de resultados que contiene información financiera condensada para el año finalizado el 31 de diciembre de 2023 debe leerse junto con el Informe anual y las cuentas de 2023 de Deltex Medical Group Plc, que se prepararon de acuerdo con las normas adoptadas por el Reino Unido. Estándares de Contaduría Internacional. Los estados financieros consolidados han sido preparados bajo la convención de costo histórico y sobre la base de negocio en marcha.
La información financiera contenida en este documento no constituye cuentas legales en el sentido de la sección 434 de la Ley de Sociedades de 2006 ('la Ley'). Las cuentas legales del año finalizado el 31 de diciembre de 2022 se han presentado en el Registro de Empresas y las del año finalizado el 31 de diciembre de 2023 se presentarán en el Registro de Empresas después de la Junta General Anual. El informe del auditor independiente sobre esas cuentas reglamentarias no tenía salvedades, no llamaba la atención sobre ningún asunto a modo de énfasis y no contenía una declaración en virtud de la sección 498(2) o (3) de la Ley. The report for year ended 31 December 2022 of the independent auditor on those statutory accounts was unqualified, did not draw attention to any matters by way of emphasis and did not contain a statement under section 498(2) or (3) of the Act.
2. Políticas contables
Las principales políticas contables del Grupo se pueden encontrar en el Informe Anual y Cuentas del Grupo 2023.
Preocupación continua
El Grupo cumple con sus requisitos diarios de capital de trabajo a través de una combinación de flujos de efectivo operativos, un servicio de descuento de facturas y, si es necesario, la obtención de financiación adicional.
The Directors have reviewed detailed budgets and forecasts until 30 June 2025 that were prepared by the Group. This review indicates that the Group is expected to continue trading as a going concern based on projected net cash flows derived from revenue generated by the Group. As a result of the Group's restructuring which took place in 2023, the Group's cost base has been reduced to a level appropriate for the current revenues of the Group.
Los Consejeros consideran que tienen motivos razonables para creer que el Grupo dispondrá de los recursos adecuados para continuar con su existencia operativa en el futuro previsible y, por tanto, es apropiado preparar los estados financieros sobre la base de empresa en funcionamiento.
3. Ingresos y EBITDA
Por el año terminado el 31 de diciembre 2023
Sondas | Directo mercado Monitores |
Otro | mercados indirectos Sondas Monitores |
Otro |
Total | |
000 £ | 000 £ | 000 £ | 000 £ 000 £ | 000 £ | 000 £ | |
UK | 394 | 113 | 42 | - - | - | 549 |
Estados Unidos de America | 287 | 20 | 40 | - - | - | 347 |
Francia | - | - | - | 283 - | 2 | 285 |
Portugal | - | - | - | 185 - | - | 185 |
latín América | - | - | - | 91 16 | - | 107 |
Escandinavia | - | - | - | 64 4 | 1 | 69 |
Hong Kong | - | - | - | 6 62 | - | 68 |
Sur Corea | - | - | - | 47 5 | 4 | 56 |
Otro países | 10 | 6 | 3 | 56 32 | 4 | 111 |
691 | 139 | 85 | 732 119 | 11 | 1,776 |
Por el año terminado el 31 de diciembre 2022
Directo mercados indirecto mercados
Sondas | Monitores | Otro | Sondas | Monitores | Otro | Total | |
000 £ | 000 £ | 000 £ | 000 £ | 000 £ | 000 £ | 000 £ | |
UK | 461 | 106 | 75 | - | - | - | 642 |
Estados Unidos de America | 463 | 122 | 51 | - | - | - | 636 |
Francia | - | - | - | 464 | 15 | 8 | 487 |
América Latina | - | - | - | 90 | 212 | 2 | 304 |
Sur Corea | - | - | - | 132 | - | - | 132 |
香港 | - | - | - | 13 | 32 | 3 | 48 |
Austria | - | - | - | 44 | - | 2 | 46 |
Islas Caimán | - | - | - | 24 | 18 | 1 | 43 |
Otro países | 19 | 30 | - | 90 | 2 | 3 | 144 |
943 | 258 | 126 | 857 | 279 | 19 | 2,482 |
A continuación se detallan los ingresos del Grupo desagregados entre venta de bienes y prestación de servicios. Todos los ingresos por la venta de bienes se reconocen en un momento dado; los ingresos por mantenimiento se reconocen en el momento en que se realiza el servicio.
2023 000 £ | 2022 000 £ | |
Venta de bienes | 1,732 | 2,430 |
Mantenimiento ingresos | 44 | 52 |
1,776 | 2,482 |
The reconciliation of the profit measure used by the Group's CODM to the result reported in the Del grupo
consolidated SOCI is set out aqui:
2023 000 £ | 2022 000 £ | |
Equilibrado Comparable No en efectivo artículos: | (860) | (607) |
Depreciación de propiedades, planta y equipo | (110) | (88) |
Amortisation of development costos | (23) | (40) |
Impairment loss on trade cuentas por cobrar | - | (39) |
Non-executive directors' fees and employer's NIC | (91) | (136) |
Ganancia sobre pagaré de préstamo convertible | 89 | - |
Write off of research and development projects not taken forward | (141) | - |
Pagos basados en acciones gastos | - | (125) |
Change in accumulated absence cost liability Cash item: | 1 | 17 |
Otro impuesto ingresos | 83 | 71 |
(192) | (340) | |
Funcionamiento de | (1,052) | (947) |
Finanzas costos | (230) | (199) |
Pérdida antes deuda | (1,282) | (1,146) |
Tax credit on de | - | 1 |
Pérdida por el año | (1,282) | (1,145) |
La siguiente tabla proporciona información sobre cuentas por cobrar comerciales y pasivos contractuales de contratos con clientes. No había activos del contrato ni al 31 de diciembre de 2023 ni al 31 de diciembre de 2022.
31 Diciembre | 31 Diciembre | |
2023 | 2022 | |
000 £ | 000 £ | |
Trade receivables which are in 'Trade and other receivables' | 177 | 456 |
Contract liabilities (Note 17.3). | (44) | (39) |
Los siguientes montos agregados de precios de transacción se relacionan con las obligaciones de desempeño de contratos existentes que están insatisfechas o parcialmente insatisfechas al 31 de diciembre de 2023:
2024 | 2025 | 2026 | 2027 | Total | |
000 £ | 000 £ | 000 £ | 000 £ | 000 £ | |
Revenue expected to be Reconocido | 31 | 4 | 2 | 7 | 44 |
Revenue recognised in 2023 which was included in contract liabilities at 31 December 2022 amounted a
£24,000. Revenue recognised in 2022 included in contract liabilities at 31 December 2021 amounted to £ 30,000.
4. Dividendos
Los directores no pueden recomendar el pago de un dividendo (2022: cero).
5. Pérdida por acción básica y diluida
The loss per share calculation is based on the loss of £1,257,000 and the weighted average number of shares in issue of 1,181,214,755. For 2022, the loss per share calculation is based on the loss of £1,149,000 and the weighted average number of shares in issue of 685,490,974. While the Group is loss-making, the diluted loss per share and the loss per share are the same.
Distribución de Informe Anual y Cuentas
En breve, el Grupo publicará una copia del Informe Anual y las Cuentas del año finalizado el 31 de diciembre de 2023 para los accionistas, junto con un Aviso de la Asamblea General Anual que se llevará a cabo a las 11.00:8 a. m. del 2024 de mayo de 25 en las oficinas de DAC Beachcroft LLP. 4 Walbrook, Londres, EC8N XNUMXAF.
Una copia del Informe Anual y las Cuentas y el Aviso de la Asamblea General Anual también estarán disponibles en breve en el sitio web del Grupo en www.deltexmedical.com/investor-relations/
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.